10-Q: Illumina Q3 2025 Sees Revenue Growth, Profit Rebound

Illumina reported a slight revenue increase in Q3 2025 and a significant return to net income for the nine months ended September 28, 2025, despite ongoing macroeconomic and geopolitical challenges.

Summary

• Total revenue for Q3 2025 increased by 0.4% to $1,084 million compared to $1,080 million in Q3 2024.
• Year-to-date (YTD) 2025 revenue decreased by 3% to $3,184 million from $3,268 million in YTD 2024, primarily due to lower service revenue and instrument sales, partially offset by consumables growth.
• Net income for Q3 2025 was $150 million ($0.98 diluted EPS), a decrease from $705 million ($4.42 diluted EPS) in Q3 2024.
• Net income for YTD 2025 was $516 million ($3.29 diluted EPS), a significant improvement from a net loss of $1,410 million ($-8.86 diluted EPS) in YTD 2024, largely due to the GRAIL spin-off and reduced operating expenses.
• Gross margin for YTD 2025 improved to 66.3% from 65.3% in YTD 2024, driven by the GRAIL spin-off, though Core Illumina's gross margin decreased due to tariffs and intangible asset impairment.
• Operating income for YTD 2025 was $606 million, a substantial turnaround from an operating loss of $1,008 million in YTD 2024.
• Cash, cash equivalents, and short-term investments totaled $1,278 million as of September 28, 2025.
• The company is acquiring SomaLogic and other specified assets for $350 million in cash, with potential additional payments, expected to close in H1 2026.
• A $42 million valuation allowance was recorded in Q3 2025 against deferred tax assets due to new U.S. tax legislation impacting R&D capitalization.

Sentiment

Score: 6

Explanation: The company shows a significant financial turnaround from substantial losses in the prior year, driven by the GRAIL spin-off and cost reduction efforts. Revenue growth is minimal and impacted by geopolitical and macroeconomic factors, particularly in China. The strategic acquisition of SomaLogic is a positive long-term move, but ongoing legal challenges and tariff impacts present headwinds. The overall sentiment is cautiously optimistic due to the return to profitability and strategic expansion, despite current market challenges.

Positives

• Q3 2025 total revenue increased slightly to $1,084 million, up from $1,080 million in Q3 2024.
• YTD 2025 net income significantly improved to $516 million, compared to a net loss of $1,410 million in YTD 2024.
• YTD 2025 income from operations was $606 million, a substantial turnaround from a $1,008 million loss in YTD 2024.
• Core Illumina consumables revenue increased in Q3 2025 and YTD 2025, driven by demand for high-throughput consumables (NovaSeq X).
• Successful implementation of cost reduction initiatives, including an incremental $100 million program in Q1 2025.
• Operating cash flow for YTD 2025 increased to $758 million from $473 million in YTD 2024, indicating improved cash generation.
• The company maintains a strong liquidity position with $1,278 million in cash, cash equivalents, and short-term investments.
• New U.S. tax legislation no longer requiring capitalization of R&D expenses is favorable.

Negatives

• YTD 2025 total revenue decreased by 3% to $3,184 million compared to YTD 2024.
• Q3 2025 net income decreased significantly to $150 million from $705 million in Q3 2024.
• Core Illumina gross margin decreased in Q3 2025 and YTD 2025 primarily due to higher tariff costs, increased inventory reserves (Q3), and a $23 million intangible asset impairment (YTD).
• Service and other revenue decreased in Q3 2025 and YTD 2025, primarily due to reduced strategic partnerships.
• Instruments revenue decreased in YTD 2025 due to fewer shipments of highand mid-throughput instruments, reflecting customer capital and cash flow constraints.
• Revenue in the Greater China region decreased by $23 million in Q3 2025 and $41 million in YTD 2025 due to inclusion on the unreliable entities list and export prohibition.
• A $42 million valuation allowance was recorded against deferred tax assets in Q3 2025 due to uncertainty regarding the future realization of U.S. foreign tax credits.
• Core Illumina SG&A expense increased in Q3 2025 due to an unfavorable $52 million impact from the remeasurement of contingent consideration liabilities related to GRAIL CVRs.
• Ongoing legal proceedings related to the GRAIL acquisition continue to be a distraction and potential liability.

Risks

• Uncertainty regarding the impact of inclusion on the unreliable entities list by regulatory authorities in China and the decision to not permit export of sequencing instruments into China.
• Potential reductions in funding for the National Institutes of Health (NIH) or targeted cancellations of U.S. federal government grants/contracts could negatively impact customers and reduce demand.
• Impact of tariffs imposed by the U.S. government and trading partners, and other trade protection measures, affecting costs and supply chain.
• Risks associated with contracts or agreements containing provisions implicated by the GRAIL divestiture, including realizing economic benefits of commercial arrangements with GRAIL and obligations for contingent value rights (CVRs).
• Risk of additional litigation arising against the company in connection with the GRAIL acquisition.
• Uncertainty regarding the completion of the proposed SomaLogic acquisition on anticipated terms and timeline, including obtaining required regulatory approvals.
• Challenges in successfully integrating SomaLogic into existing operations and its technology/products into the portfolio.
• Uncertainty or adverse economic and business conditions, including slowing economic growth, competitive landscape, public health crises, or armed conflict.
• High levels of volatility are possible in the GRAIL contingent consideration liability in future periods due to inherent uncertainty in underlying assumptions.
• Implementation of the global ERP system upgrade may materially affect internal controls over financial reporting.

Future Outlook

The company expects macroeconomic factors, tariffs, and challenges in the China region to continue impacting sales and results for the remainder of 2025 and beyond. It aims to return to revenue growth and fully mitigate tariff impacts by 2026 through operational excellence, cost reduction initiatives, and supply chain optimization. The acquisition of SomaLogic is expected to enhance presence in the proteomics market and advance the multiomics strategy, with closing anticipated in the first half of 2026.

Management Comments

• "We believe our acquisition of SomaLogic will enhance our presence in the expanding proteomics market and advance our multiomics strategy."
• "We expect these factors [macroeconomic, China, NIH funding] to continue to impact our sales and results of operations for the remainder of 2025 and beyond, the size and duration of which is significantly uncertain."
• "We have made significant progress towards our strategic goals. During 2024 and 2025, we focused on our operational excellence initiatives to improve productivity and achieve cost savings, including expanding operating margins, and on our capital allocation strategy, including significant share repurchases."
• "We expect to continue to make further progress towards our strategic goals, including a focus on returning to revenue growth."
• "Based on the current tariff environment, our aim is to more fully mitigate the impact in 2026."

Industry Context

Illumina operates in the highly competitive and innovation-driven genetic and genomic analysis market. The company's strategic acquisition of SomaLogic indicates a move towards expanding its multiomics capabilities, particularly in the proteomics market, aligning with a broader industry trend of integrating different biological data types for comprehensive insights. However, the industry faces headwinds from macroeconomic factors, government funding uncertainties (NIH), and geopolitical tensions (China market restrictions), which are impacting customer purchasing behavior and capital allocation across the sector.

Comparison to Industry Standards

• Not explicitly detailed in the filing. The filing does not provide specific comparable companies, projects, or results to global benchmarks.

Corporate Governance

Legal Proceedings

• Multiple shareholder derivative complaints (e.g., Icahn Partners LP, City of Omaha, City of Roseville, The Pavers and Road Builders Benefit Funds) filed against current and former directors/officers, alleging breach of fiduciary duties related to the GRAIL acquisition. These actions have been consolidated, and motions to dismiss are ongoing. A settlement in principle for one action (Icahn Partners LP) involves no payment.
• Federal securities class actions (e.g., Kangas v. Illumina, Inc. et al.) alleging materially false and misleading statements and omissions related to the GRAIL acquisition. The court granted a motion to dismiss with leave to amend, and a Third Amended Complaint has been filed.
• State securities class actions (e.g., Loren Scott Mar v. Illumina, et al.) making similar allegations regarding registration statements and prospectus for the GRAIL acquisition. Illumina's demurrer was overruled, and an answer was filed, with an interlocutory appellate review sought.
• Stockholder litigation demands (Michael Warner, Jane Davidson) requesting civil actions against officers and directors involved with the GRAIL acquisition, which the Board has deferred decisions on pending the outcome of existing lawsuits.

Related Party Transactions

• Revenue recognized from transactions with strategic investees was $7 million for Q3 2025 and $22 million for YTD 2025.
• The company retained 14.5% of GRAIL common stock after the Spin-Off and has commercial arrangements with GRAIL.
• Obligation to indemnify GRAIL for cash payments related to a performance-based award for 2.5 years following the Spin-Off, with a non-contingent liability of $1 million.
• Contingent consideration liabilities related to GRAIL (CVRs) entitle holders to future cash payments based on GRAIL's revenues through August 2033.

Stakeholder Impact

• Shareholders are impacted by the significant turnaround to YTD profitability, ongoing share repurchase program, and potential long-term growth from the SomaLogic acquisition. However, they are also exposed to risks from ongoing legal proceedings, macroeconomic headwinds, and geopolitical challenges affecting revenue.
• Employees are affected by workforce reductions as part of cost reduction initiatives. Share-based compensation optimization also impacts employee incentives.
• Customers are facing funding concerns (NIH), leading to conservative inventory and capital management, and delayed projects. Customers in Greater China are directly impacted by export prohibitions.
• Suppliers may be impacted by supply chain optimization efforts aimed at mitigating tariff costs.
• Creditors benefit from the company's strong liquidity position and compliance with debt covenants, indicating financial stability.

Next Steps

• Complete the acquisition of SomaLogic, expected in the first half of 2026.
• Integrate SomaLogic into existing operations and its technology/products into the portfolio.
• Continue operational excellence initiatives to improve productivity and achieve cost savings.
• Focus on returning to revenue growth.
• Mitigate the impact of tariffs, aiming for fuller mitigation in 2026.
• Monitor and defend against ongoing shareholder derivative and securities class action lawsuits.
• Continue implementation of the global ERP system upgrade, expected to be operational in the first half of 2027.
• Board to monitor stockholder lawsuits and revisit litigation demands as warranted.
• Company's response due December 11, 2025, for the Third Amended Complaint in federal securities class actions.
• Hearing on motion to dismiss in consolidated Pavers action scheduled for February 13, 2026.

Key Dates

Recommendation

Illumina's significant return to YTD profitability and strategic expansion into proteomics with the SomaLogic acquisition are positive long-term indicators. However, the company faces persistent headwinds from macroeconomic uncertainty, tariffs, and critical market restrictions in China, which are impacting revenue growth. The ongoing and complex legal proceedings related to the GRAIL acquisition also introduce considerable uncertainty and potential liabilities. While the company is taking proactive steps with cost reductions and share repurchases, these factors create a mixed outlook. A 'hold' recommendation is appropriate as investors should monitor the execution of strategic initiatives, resolution of legal matters, and the impact of external market pressures before making further investment decisions.

Keywords

Illumina, ILMN, Genomic Analysis, DNA Sequencing, Microarray, Life Sciences, Oncology, Proteomics, SomaLogic Acquisition, GRAIL Spin-Off, SEC Filing, 10-Q, Financial Results, Biotechnology, Diagnostics, Research & Development, Tariffs, China Market, NIH Funding, Share Repurchase